Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS041783)
Received: 19 April 2021
Accepted: 18 May 2021
First Online: 25 May 2021
: All animal use was approved by the IACUC committee of Harvard Medical School and Brigham and Women's Hospital in accordance with the USDA Animal Welfare Act and PHS Policy on Humane Care and Use of Laboratory Animals.
: Not applicable.
: J.S. has a financial interest in Apres Therapeutics and iNeuro Therapeutics, both companies developing therapies for Alzheimer’s disease. J.S.’s interests were reviewed and are managed by BWH and Mass General Brigham in accordance with their conflict of interest policies.